Clinical pharmacology of nicotine: Implications for understanding, preventing, and treating tobacco addiction

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 4, 2008, Pages 531-541

  Benowitz, N L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; NICOTINE; NICOTINIC RECEPTOR;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG EFFECT; EPIDEMIC; HARM REDUCTION; HUMAN; LUNG CANCER; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TOBACCO DEPENDENCE;

AFRICAN AMERICANS; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN AMERICANS; BENZAZEPINES; BUPROPION; COTININE; CUES; DRUG TOLERANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HARM REDUCTION; HUMANS; MENTHOL; MIXED FUNCTION OXYGENASES; NEURONAL PLASTICITY; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RECEPTORS, NICOTINIC; REINFORCEMENT (PSYCHOLOGY); SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; UNITED STATES;

EID: 40949084426     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.3     Document Type: Review

References (51)

1. Arcavi, L. & Benowitz, N.L. Cigarette smoking and infection. Arch. Intern. Med. 164, 2206-2216 (2004).
2. Hamilton, M. et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 12, 2166-2171 (2006).
3. van der Bol, J.M. et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 25, 2719-2726 (2007).
4. Himmelmann, A., Jendle, J., Mellen, A., Petersen, A.H., Dahl, U.L. & Wollmer, P. The impact of smoking on inhaled insulin. Diabetes Care 26, 677-682 (2003).
5. Benowitz, N.L. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog. Cardiovasc. Dis. 46, 91-111 (2003).
6. Mineur, Y.S. & Picciotto, M.R. Genetics of nicotinic acetylcholine receptors: relevance to nicotine addiction. Biochem. Pharmacol. 75, 323-333 (2008).
7. Kauer, J.A. & Malenka, R.C. Synaptic plasticity and addiction. Nat. Rev. Neurosci. 8, 844-858 (2007).
8. Naqvi, N.H., Rudrauf, D., Damasio, H. & Bechara, A. Damage to the insula disrupts addiction to cigarette smoking. Science 315, 531-534 (2007).
9. Hughes, J.R. Clinical significance of tobacco withdrawal. Nicotine Tob. Res. 8, 153-156 (2006).
10. Hukkanen, J., Jacob, P. III, & Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79-115 (2005).
11. Dempsey, D. et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76, 64-72 (2004).
12. Benowitz, N.L., Swan, G.E., Jacob, P. III, Lessov-Schlaggar, C.N. & Tyndale, R.F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 80, 457-467 (2006).
13. Malaiyandi, V., Sellers, E.M. & Tyndale, R.F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin. Pharmacol. Ther. 77, 145-158 (2005).
14. Benowitz, N.L., Lessov-Schlaggar, C.N., Swan, G.E. & Jacob, P. III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79, 480-488 (2006).
15. Institute of Medicine. The nature of nicotine addiction. In Growing Up Tobacco Free - Preventing Nicotine Addiction in Children and Youths (eds. Lynch, B.S., Bonnie, R.J.) 28-68 (National Academy Press, Washington DC, 1994).
16. Levin, E.D. et al. Adolescent vs. adult-onset nicotine self-administration in male rats: duration of effect and differential nicotinic receptor correlates. Neurotoxicol. Teratol. 29, 458-465 (2007).
17. Department of Health and Human Services PHS. Tobacco use among U.S. racial/ethnic minority groups - African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics: a report of the surgeon general: USDHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Promotion, Office of Smoking and Health. Government Printing Office, Washington DC, 1998.
18. Haiman, C.A. et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N. Engl. J. Med. 354, 333-342 (2006).
19. Perez-Stable, E.J., Herrera, B., Jacob, P. III & Benowitz, N.L. Nicotine metabolism and intake in black and white smokers. JAMA 280, 152-156 (1998).
20. Pletcher, M.J., Hulley, B.J., Houston, T., Kiefe, C.I., Benowitz, N. & Sidney, S. Menthol cigarettes, smoking cessation, atherosclerosis, and pulmonary function: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arch. Intern. Med. 166, 1915-1922 (2006).
21. Benowitz, N.L., Herrera, B. & Jacob, P. III. Mentholated cigarette smoking inhibits nicotine metabolism. J. Pharmacol. Exp. Ther. 310, 1208-1215 (2004).
22. Benowitz, N.L., Perez-Stable, E.J., Herrera, B. & Jacob, P. III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J. Natl. Cancer Inst. 94, 108-115 (2002).
23. Grant, B.F., Hasin, D.S., Chou, S.P., Stinson, F.S. & Dawson, D.A. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 61, 1107-1115 (2004).
24. Lewis, A., Miller, J.H. & Lea, R.A. Monoamine oxidase and tobacco dependence. Neurotoxicology 28, 182-195 (2007).
25. Fujieda, M. et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 25, 2451-2458 (2004).
26. Lessov-Schlaggar, C.N., Pergadia, M.L., Khroyan, T.V. & Swan, G.E. Genetics of nicotine dependence and pharmacotherapy. Biochem. Pharmacol. 75, 178-195, (2008).
27. Ho, M.K. & Tyndale, R.F. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 7, 81-98 (2007).
28. Bierut, L.J. et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet. 16, 24-35 (2007).
29. Saccone, S.F. et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16, 36-49 (2007).
30. Uhl, G.R., Liu, Q.R., Drgon, T., Johnson, C., Walther, D. & Rose, J.E. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genet. 8, 10 (2007).
31. Swan, G.E., Benowitz, N.L., Lessov, C.N., Jacob, P. III, Tyndale, R.F. & Wilhelmsen, K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet. Genomics 15, 115-125 (2005).
32. Institute of Medicine. Clearing the Smoke. Assessing the Science Base for Tobacco Harm Reduction. National Academy Press, Washington DC, 2001.
33. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 283, 3244-3254 (2000).
34. Rollema, H., Coe, J.W., Chambers, L.K., Hurst, R.S., Stahl, S.M. & Williams, K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol. Sci. 28, 316-325 (2007).
35. Siu, E.C. & Tyndale, R.F. Non-nicotinic therapies for smoking cessation. Annu. Rev. Pharmacol. Toxicol. 47, 541-564 (2007).
36. Lerman, C. et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann. Intern. Med. 140, 426-433 (2004).
37. Lee, A.M. et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatry 62, 635-641 (2007).
38. Lerman, C. et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79, 600-608 (2006).
39. Patterson, F. et al. Toward personalized therapy for tobacco dependence: use of the nicotine metabolite ratio 2007. Clin. Pharmacol. Ther., this issue.
40. Luo, J. et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 369, 2015-2020 (2007).
41. England, L.J., Levine, R.J., Mills, J.L., Klebanoff, M.A., Yu, K.F. & Cnattingius, S. Adverse pregnancy outcomes in snuff users. Am. J. Obstet. Gynecol. 189, 939-943 (2003).
42. Henley, S.J. et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob. Control 16, 22-28 (2007).
43. Batra, A., Klingler, K., Landfeldt, B., Friederich, H.M., Westin, A. & Danielsson, T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. Clin. Pharmacol. Ther. 78, 689-696 (2005).
44. Zeidler, R., Albermann, K. & Lang, S. Nicotine and apoptosis. Apoptosis 12, 1927-1943 (2007).
45. Cooke, J.P. & Bitterman, H. Nicotine and angiogenesis: a new paradigm for tobacco-related diseases. Ann. Med. 36, 33-40 (2004).
46. Institute of Medicine. Ending the Tobacco Problem. A Blueprint for the Nation. (National Academy Press, Washington DC, 2007).
47. Benowitz, N.L. & Henningfield, J.E. Establishing a nicotine threshold for addiction. N. Engl. J. Med. 331, 123-125 (1994).
48. Henningfield, J.E., Benowitz, N.L., Slade, J., Houston, T.P., Davis, R.M. & Deitchman, S.D. Reducing the addictiveness of cigarettes. Tob. Control 7, 281-293 (1998).
49. Benowitz, N.L. et al. Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol. Biomarkers Prev. 14, 1376-1383 (2005).
50. Benowitz, N.L., Hall, S.M., Stewart, S., Wilson, M., Dempsey, D. & Jacob, P. III Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol. Biomarkers Prev. 16, 2479-2485 (2007).
51. Tengs, T.O., Ahmad, S., Savage, J.M., Moore, R. & Gage, E. The AMA proposal to mandate nicotine reduction in cigarettes: a simulation of the population health impacts. Prev. Med. 40, 170-180 (2005).